An update on epidermal growth factor receptor inhibitors.
An update on epidermal growth factor receptor inhibitors.
复制标题
DOI：
10.1007/s11912-002-0047-6
复制
发表时间：
2002-01-01
影响因子：
4.7
通讯作者：
Seidman, Andrew D
中科院分区：
文献类型：
--
作者：
Modi, Shanu;Seidman, Andrew D
表皮生长因子受体（EGFR）是质膜受体酪氨酸激酶家族的一部分，其控制许多重要的细胞功能，从细胞生长和增殖到细胞死亡。EGFR信号转导通路的失调与肿瘤发生和癌症进展有关，使其成为新型抗癌治疗的临床相关靶点。本文综述了针对EGFR细胞外和细胞内结构域的特定方面的癌症治疗的最新进展。强调了在临床试验的高级阶段有前途的新化合物。
The epidermal growth factor receptor (EGFR) is part of a family of plasma membrane receptor tyrosine kinases that control many important cellular functions, from cell growth and proliferation to cell death. Dysregulation of the EGFR signal transduction pathway has been implicated in tumorigenesis and cancer progression, making it a clinically relevant target for novel anticancer treatments. This paper reviews recent progress in the development of cancer therapies that are directed toward particular aspects of the extracellular and intracellular domains of EGFR. Promising new compounds in the advanced stages of clinical testing are emphasized.